Metronidazole

• PO
  • 500mg PO q6-8h x 7-10 days
  • First Dose: 500mg PO x 1
• IV
  • 15mg/kg IV x1, then 7.5mg/kg IV q6h
  • First Dose: 15mg/kg IV x1
• Max: 1 gram/dose

• 500-750mg PO q8h x 5-10 days

• 15mg/kg IV x 1
• Complete infusion 1h prior to surgery, then 7.5mg/kg IV q6h x 2
• Max: 1 g/dose

• 750mg PO q8h x 5-10 days

• 500mg PO q12 x 14 days
• See PID for full regimen

• 500mg PO q12 x 7 days
• Alt: May use 250mg PO q8h x 7 days in pregnant patients
• Prophylaxis (Sexual Assault)
  • 2 g PO x 1

• Treatment
  • Immunocompetent: 2 g PO x 1
  • Immunocompromised: 500mg PO q12h x 7 days
• Prophylaxis (Sexual Assault)
  • 2 g PO x 1

• 250mg PO q8h x 5-7 days
• Alt: 2 g PO q 24h x 3 days

• Mild-mod
  • 500mg PO q8h x 10-14 days
• Severe
  • 500mg IV q8h (give with vancomycin PO)

• 250-375mg PO q6h x 10-14 days (in combination)

• 2 g PO x 1 (with azithromycin)

• 500 mg IV every 6 hours

• 7.5 mg/kg PO/IV q48h
• First Dose: 7.5 mg/kg PO/IV x 1

• <7 days old
  • 7.5-15 mg/kg/day PO/IV q12-24h
  • First Dose: 7.5-15 mg/kg PO/IV x 1
• >7 days old
  • 15-30 mg/kg/day PO/IV q12h
  • First Dose: 7.5-15 mg/kg PO/IV x 1

• 30 mg/kg/day PO/IV q6h
• First Dose: 7.5 mg/kg PO/IV x 1
• Max: 4 g/day

<45kg

• 15 mg/kg/day PO divided q12h x 7 days
• First Dose: 7 mg/kg PO x 1
• Max: 1 g/day

>45kg

• 500mg PO divided q8h x 7 days
• First Dose: 500mg PO x 1
• Max: 2 g/day

<45kg'

• 15 mg/kg/day PO divided q8h x 7 days
• First Dose: 7 mg/kg PO x 1

>45kg

• 2 g PO x 1

Same as Standard Pediatric Age/Weight Dosing

• Seizures
• Aseptic meningitis
• Perifpheral neuropathy
• Optic neuropathy
• Encephalopathy
• Hypersensitivity Reaction
• Stevens-Johnson Syndrome
• Toxic Epidermal Necrolysis
• Leukopenia
• Carcinogenicity (in animals)

• Disulfiram effect
• Nausea and Vomiting
• Epigastric discomfort
• Diarrhea
• Metallic taste
• Rash
• Headache
• Dizziness
• Dark reddish-brown urine
• Candidiasis
• Thrombophlebitis (IV use)

• S susceptible/sensitive (usually)
• I intermediate (variably susceptible/resistant)
• R resistant (or not effective clinically)
• S+ synergistic with cell wall antibiotics
• U sensitive for UTI only (non systemic infection)
• X1 no data
• X2 active in vitro, but not used clinically
• X3 active in vitro, but not clinically effective for Group A strep pharyngitis or infections due to E. faecalis
• X4 active in vitro, but not clinically effective for strep pneumonia